The editor's roundtable: revisiting the role of beta blockers in hypertension.
Roberts
William C
WC
Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, Texas, USA. wc.roberts@baylorhealth.edu
Black
Henry R
HR
Bakris
George L
GL
Mason
R Preston
RP
Giles
Thomas D
TD
Sulkes
Destry J
DJ
D000319:Adrenergic beta-Antagonists / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000627:therapeutic use; D001578:Benzopyrans / Q000627:therapeutic use; D001786:Blood Glucose / Q000032:analysis; D001794:Blood Pressure / Q000187:drug effects; D001919:Bradycardia / Q000139:chemically induced; D001921:Brain / Q000187:drug effects; D001986:Bronchial Spasm / Q000139:chemically induced; D004983:Ethanolamines / Q000627:therapeutic use; D006327:Heart Block / Q000139:chemically induced; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008055:Lipids / Q000097:blood; D000068577:Nebivolol; D012735:Sexual Dysfunction, Physiological / Q000139:chemically induced
D000319:Adrenergic beta-Antagonists; D000959:Antihypertensive Agents; D001578:Benzopyrans; D001786:Blood Glucose; D004983:Ethanolamines; D008055:Lipids; D000068577:Nebivolol